Metagenomi enters LNP license with Acuitas, terminates Affini-T TCR deal

Metagenomi Therapeutics, Inc.

Non-exclusive Acuitas license for LNP technology; low-seven-figure annual maintenance fee until first Phase 1 dosing.
Milestone payments low to mid seven figures for regulatory/commercial events; royalties low mid-single digit % of net sales.
Terminated Affini-T agreement effective Sept 30, 2025 due to Affini-T's assignment for benefit of creditors.
Metagenomi regains full control over IP and rights to develop TCR-based therapeutics previously licensed to Affini-T.
No future payments expected from Affini-T under terminated agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.